Biomarck is a biopharmaceutical company focused on the development of drugs to treat ARDS, COPD, cancer and other hard to treat diseases. With over 100 patented peptides in our global portfolio, we utilize anti-MARCKS proteins to selectively inhibit cancer progression and the inflammatory cytokine release involved in respiratory diseases and other severe illnesses. We are dedicated to developing safe and targeted treatments for patients in need with our platform technology.
Professor Kenneth Adler was the first to inhibit the biological function of the MARCKS protein from his lab at North Carolina Sate University. Dr. Adler has published over 120 papers, mostly in the areas of airway inflammation, mucus secretion and cancer. He is an inventor or co-inventor on 51 patents. Understanding the method of action (MOA) related to inhibiting MARCKS protein is how Biomarck’s peptides are developed for the treatment of different diseases.